32 patents
Utility
Treatment of Kras Mutant Cancers
18 Jan 24
Sandra E. Wiley, Daniel P. Gold
Filed: 19 Nov 21
Utility
Isoflavonoid Compounds and Methods for the Treatment of Cancer
23 Nov 23
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid.
George JEOFFREYS, Alison JOHNSON, Andrew HEATON, Ofir MORENO
Filed: 1 Aug 23
Utility
Isoflavonoid compositions and methods for the treatment of cancer
15 Aug 23
Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin.
Ofir Moreno
Filed: 5 Mar 21
Utility
Combination Therapies
27 Jul 23
Provided herein are compositions, methods, and kits for treating cancer comprising a mitochondrial inhibitor and a Bcl-2 inhibitor.
Daniel P. GOLD
Filed: 10 Jun 21
Utility
Isoflavonoid Compounds and Methods for the Treatment of Cancer
11 May 23
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid.
George JEOFFREYS, Alison JOHNSON, Andrew HEATON, Ofir MORENO
Filed: 13 Jan 23
Utility
Preparation of a 1,3,5-TRIAZINYL Benzimidazole
27 Apr 23
Described herein is the preparation of a 1,3,5-triazinyl benzimidazole and chemical intermediates used in the synthetic process.
David DUNCAN
Filed: 2 Apr 21
Utility
Isoflavonoid compounds and methods for the treatment of cancer
21 Feb 23
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid.
George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
Filed: 17 Sep 20
Utility
(Alpha-substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-TRIAZINYL Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use In Treating Proliferative Diseases
13 Oct 22
S. David BROWN, David J. MATTHEWS
Filed: 21 Jun 22
Utility
Combination Therapy
25 Aug 22
Provided herein are methods of treating diseases, such as cancer, using a combination therapy.
Daniel P. GOLD
Filed: 2 May 22
Utility
(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
2 Aug 22
S. David Brown, David J. Matthews
Filed: 13 Feb 20
Utility
Combination Therapy
23 Jun 22
Provided herein are methods of treating diseases, such as cancer, using a combination therapy.
Daniel P. GOLD
Filed: 1 Mar 22
Utility
Combination therapy
7 Jun 22
Provided herein are methods of treating diseases, such as cancer, using a combination therapy.
Daniel P. Gold
Filed: 14 Aug 18
Utility
Combination therapy
19 Apr 22
Provided herein are methods of treating diseases, such as cancer, using a combination therapy.
Daniel P. Gold
Filed: 22 May 18
Utility
Combination Therapies for High and Very High Risk MDS
20 Jan 22
Provided herein are methods of treating high and very high risk MDS comprising administering pracinostat and a DNA hypomethylating agent.
Richard GHALIE
Filed: 26 Nov 19
Utility
Isoflavonoid Compositions and Methods for the Treatment of Cancer
25 Nov 21
Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin.
Ofir MORENO
Filed: 5 Mar 21
Utility
Treatment of B Cell Malignancies
30 Sep 21
Provided herein are methods of treating cancer using a phosphoinositide-3-kinase (PI3K) inhibitor.
Daniel P. GOLD
Filed: 13 Aug 19
Utility
Combination Therapies
2 Sep 21
Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
Daniel P. GOLD, Miguel QUINTELA-FANDINO
Filed: 16 Mar 21
Utility
Treatment of Relapsed Follicular Lymphoma
1 Jul 21
Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor.
Daniel P. GOLD
Filed: 13 Aug 19
Utility
Combination Therapy
3 Jun 21
Provided herein are methods of treating diseases, such as cancer, using a combination therapy.
Daniel P. GOLD
Filed: 13 Aug 19
Utility
Isoflavonoid compositions and methods for the treatment of cancer
13 Apr 21
Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin.
Ofir Moreno
Filed: 18 Jun 19